Strategy to confirm the presence of anti-erythropoietin neutralizing antibodies in human serum

Journal of Pharmaceutical and Biomedical Analysis

Volumn 55, Issue 5, 2011, Pages 1265-1274

  Sanchez, Sergio ^a   Barger, Troy ^a   Zhou, Lei ^a   Hale, Michael ^a   Mytych, Daniel ^a   Gupta, Shalini ^a   Swanson, Steven J ^a   Civoli, Francesca ^a  

^a AMGEN INC   (United States)

Author keywords

Antibody depletion; Erythropoietin; Protein G sepharose; Protein L sepharose; Pure red cell aplasia

Indexed keywords

ERYTHROPOIETIN ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; NEUTRALIZING ANTIBODY; RESIN;

ANTIBODY BLOOD LEVEL; ARTICLE; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SERUM;

ANIMALS; ANTIBODIES; ANTIBODIES, NEUTRALIZING; BIOSENSING TECHNIQUES; CELL LINE; CELL PROLIFERATION; ERYTHROPOIETIN; FEMALE; HUMANS; IMMUNOASSAY; INTERLEUKIN-3; MALE; MICE; RECEPTORS, ERYTHROPOIETIN; RED-CELL APLASIA, PURE; SEPHAROSE; SERUM;

EID: 79956080781     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.03.029     Document Type: Article

References (15)

1. Wei X., Swanson S.J., Gupta S. Development and validation of a cell-based bioassay for the detection of neutralizing antibodies against recombinant human erythropoietin in clinical studies. J. Immunol. Methods 2004, 293:115-126.
2. Eschbach J.W., Adamson J.W. Anemia of end-stage renal disease (ESRD). Kidney Int. 1985, 28:1-5.
3. Lacombe C., Mayeux P. The molecular biology of erythropoietin. Nephrol. Dial. Transplant. 1999, 14(Suppl. 2):22-28.
4. Lin F.K., Suggs S., Lin C.H., Browne J.K., Smalling R., Egrie J.C., Chen K.K., Fox G.M., Martin F., Stabinsky Z., et al. Cloning and expression of the human erythropoietin gene. Proc. Natl. Acad. Sci. U.S.A 1985, 82:7580-7584.
5. Sasaki H., Bothner B., Dell A., Fukuda M. Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J. Biol. Chem. 1987, 262:12059-12076.
6. Casadevall N., Nataf J., Viron B., Kolta A., Kiladjian J.J., Martin-Dupont P., Michaud P., Papo T., Ugo V., Teyssandier I., Varet B., Mayeux P. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 2002, 346:469-475.
7. Swanson S.J. New technologies for the detection of antibodies to therapeutic proteins. Dev. Biol. (Basel) 2003, 112:127-133.
8. Wadhwa M., Bird C., Dilger P., Gaines-Das R., Thorpe R. Strategies for detection, measurement and characterization of unwanted antibodies induced by therapeutic biologicals. J. Immunol. Methods 2003, 278:1-17.
9. Mason S., La S., Mytych D., Swanson S.J., Ferbas J. Validation of the BIACORE 3000 platform for detection of antibodies against erythropoietic agents in human serum samples. Curr. Med. Res. Opin. 2003, 19:651-659.
10. Bjorck L., Kronvall G. Purification and some properties of streptococcal protein G, a novel IgG-binding reagent. J. Immunol. 1984, 133:969-974.
11. De Chateau M., Nilson B.H., Erntell M., Myhre E., Magnusson C.G., Akerstrom B., Bjorck L. On the interaction between protein L and immunoglobulins of various mammalian species. Scand. J. Immunol. 1993, 37:399-405.
12. Sawicki W., Kieler J., Briand P. Vital staining with neutral red and trypan blue of 3H-thymidine-labeled cells prior to autoradiography. Stain Technol. 1967, 42:143-146.
13. Gupta S., Indelicato S.R., Jethwa V., Kawabata T., Kelley M., Mire-Sluis A.R., Richards S.M., Rup B., Shores E., Swanson S.J., Wakshull E. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J. Immunol. Methods 2007, 321:1-18.
14. Schellekens H. The first biosimilar epoetin: but how similar is it?. Clin. J. Am. Soc. Nephrol. 2008, 3:174-178.
15. " Guidance for Industry: Assay Development for Immunogenicity Testing of Therapeutic Proteins" U.S. Food and Drug Administration [FDA] website. Available from: , 2009 (accessed 9.12.10). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM192750.pdf.